



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R³ is C₁-C₅ alkyl or C₁-C₅ alkyl substituted by alkoxy or one or more halo.

Please insert therefor:



or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_3 alkyl and C_1 - C_3 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_3 alkyl and C_1 - C_3 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_3 alkyl or C_1 - C_3 alkyl substituted by alkoxy or one or more halo.

Page 4, third paragraph (lines 11-18), to page 5, first paragraph (lines 1-4), please delete (replace):

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_3 alkyl and C_1 - C_3 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_3 alkyl and C_1 - C_3 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_3 alkyl or C_1 - C_3 alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 5, fourth paragraph (lines 12-23) , please delete (replace):

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R³ is C₁-C₅ alkyl or C₁-C₅ alkyl substituted by alkoxy or one or more halo.

Page 6, second paragraph (lines 7-17), please delete (replace):

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 17, last paragraph (line 30), to page 18, first paragraph (lines 1-10), please delete (replace):

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 21, ninth paragraph (lines 19-27), to page 22, first paragraph (lines 1-3), please delete (replace):

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R³ is C₁-C₅ alkyl or C₁-C₅ alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 25, fourth paragraph (lines 7-18), please delete (replace):

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula V, the invention relates to: